SyntekaBio

SyntekaBio Profit per Employee

The Profit per Employee of SyntekaBio (226330.KQ) as of Nov 20, 2026 is -362.04 M KRW. In the previous year, Profit per Employee was -150.27 M KRW — a change of 140.92% (lower).

Profit per Employee

-362.04 MKRW

YoY

140.92%

Last updated:

Profit per Employee of SyntekaBio is 2025 -362.04 M KRW. Profit per Employee of SyntekaBio was 2024 -150.27 M KRW. It decreases by 140.92% lower compared to the previous year.

The SyntekaBio Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
78.05 M KRW
Jan 1, 2019
-478.46 M KRW
Jan 1, 2020
-135.16 M KRW
Jan 1, 2021
-308.39 M KRW
Jan 1, 2022
-93.88 M KRW
Jan 1, 2023
-237.45 M KRW
Jan 1, 2024
-150.27 M KRW
Jan 1, 2025
-362.04 M KRW
The SyntekaBio Profit per Employee history
YEARProfit per EmployeeYoY
-362.04 MKRW+140.92%
-150.27 MKRW-36.71%
-237.45 MKRW+152.92%
-93.88 MKRW-69.56%
-308.39 MKRW+128.16%
-135.16 MKRW-71.75%
-478.46 MKRW-712.99%
78.05 MKRW-164.77%
-120.51 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Profit per Employee of SyntekaBio is -362.04 M KRW in 2025.

Profit per Employee of SyntekaBio changed from -150.27 M KRW to -362.04 M KRW, representing a 140.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — SyntekaBio

All Key Metrics — SyntekaBio